Checked.be
Active
BE 0755.821.327Private limited company
CVHD
Reekstraat 134 ·3740 Bilzen-Hoeselt, Belgium· 5 yrs active
Sector: Retail sale of pharmaceutical products
(47730)
Conclusion
The computed 12-month bankruptcy probability of CVHD is 1.7% (moderate). The 2024 annual accounts show equity of €229k and a net result of €79k. Equity is growing by ~51.4% per year across the filed fiscal years. Its solvency ranks better than 95% of 26062 sector peers (fiscal year 2024). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
Based on the State Gazette, CBE and 4 annual accounts.
Key figures
| Equity | €229k |
| Net result | €79k |
| Better than sector | 95% |
| Active | 5 yrs |
Financial profile
94
/ 100
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
Health
100
Profitability
100
Solvency
100
Growth
78
Stability
94
Bankruptcy probability (12 mo)
Risk Assessment
0 / 100
Low riskTrust signals
More than 3 years active
Founded in 2020, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.
Administrative Flags
No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
Checked score
100
/ 100
Excellent
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.
Indicative credit limit
€23k
estimate, not credit advice
Score history
93
2021
100
2022
100
2023
100
2024
purely financial, excl. current insolvency signals
Score components
Liquidity
Current ratio 34.91 (≥ 1.5)
+10
Quick ratio
Quick ratio 34.91 (≥ 1.0)
+5
Leverage
Debt/equity 0.04 (< 1.0)
+10
Profitability
ROE 34% (≥ 10%)
+10
Interest coverage
Interest coverage 2417.7× (≥ 3×)
+8
Profit trend
Net profit up YoY
+5
Equity growth
Equity growing YoY
+3
Computed by Checked from the NBB filing for FY 2024. Indicative, not credit advice.
Financial overview
Annual accounts filed on 22-07-2025 with the NBB · fiscal year 2024 · micro schema
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing
Net result: growth of ~34.1%/year over 4 fiscal years, indicative, assuming unchanged policy.
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
Sector comparison
Fiscal year 2024 · NACE 47, Retail trade · compared within the same schema type (micro schema)
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 96.4% | 32.3% | |
| Net result | €79k | €4k | |
| Equity | €229k | €39k | |
| Gross operating margin | €113k | €31k | |
| Total assets | €237k | €146k |
€112k
+34.2%
21-24
€79k
+33.4%
21-24
€82k
+33.3%
21-24
€237k
+46.2%
21-24
€229k
+52.7%
21-24
€221k
+51.0%
21-24
€31k
+36.6%
21-24
€8k
-31.8%
21-24
€7k
-41.2%
21-24
34.91
+145.6%
21-24
34.91
+145.6%
21-24
96.4%
+4.4%
21-24
0.04
-55.3%
21-24
34.5%
-12.6%
21-24
33.3%
-8.8%
21-24
2417.72
+22.1%
21-24
Figures by fiscal year and ratios
| Fiscal year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | abbreviated schema |
| Revenue | - | - | - | - |
| EBITDA | €112k | €84k | €70k | €44k |
| Net profit | €79k | €59k | €56k | €32k |
| Cash flow | €82k | €61k | €56k | €33k |
| Staff costs | - | - | - | - |
| Income taxes | €31k | €22k | €14k | €11k |
| Dividends | - | - | - | - |
| Total assets | €237k | €162k | €107k | €51k |
| Equity | €229k | €150k | €91k | €35k |
| Debt | €8k | €12k | €17k | €16k |
| of which ≤ 1y | €7k | €11k | €15k | €14k |
| of which > 1y | - | - | - | - |
| Working capital | €221k | €146k | €92k | €35k |
| Employees (FTE) | - | - | - | - |
Note: these years are not on the same basis. The filed schemas differ (micro schema, abbreviated schema), so the columns are not directly comparable.
Ratios (computed)
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Current ratio | 34.91 | 14.22 | 7.25 | 3.40 |
| Quick ratio | 34.91 | 14.22 | 7.25 | 3.40 |
| Working capital ratio | 93.1% | 90.2% | 85.7% | 68.5% |
| Solvency | 96.4% | 92.4% | 84.6% | 69.3% |
| Debt / equity | 0.04 | 0.08 | 0.18 | 0.44 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 2417.72 | 1979.82 | 1690.78 | 1055.40 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 33.3% | 36.5% | 51.8% | 63.4% |
| ROE | 34.5% | 39.5% | 61.2% | 91.5% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Balance-sheet composition 2024
Full annual accounts (22 line items)
Filed balance sheet and income statement, exactly as deposited with the NBB.
| Line item | Code | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €237k | €162k | €107k | €51k |
| Fixed assets | 21/28 | €10k | €5k | €668 | €2k |
| Tangible fixed assets | 22/27 | €10k | €5k | €668 | €2k |
| Current assets | 29/58 | €227k | €157k | €107k | €49k |
| Amounts receivable within one year | 40/41 | €1k | €0 | €3k | - |
| Investments | 50/53 | €160k | - | - | - |
| Cash & bank | 54/58 | €66k | €157k | €103k | €49k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €237k | €162k | €107k | €51k |
| Equity | 10/15 | €229k | €150k | €91k | €35k |
| Contributions / capital | 10/11 | €3k | €3k | €3k | €3k |
| Reserves | 13 | €226k | €147k | €88k | €32k |
| Amounts payable | 17/49 | €8k | €12k | €17k | €16k |
| Amounts payable within one year | 42/48 | €7k | €11k | €15k | €14k |
| Trade debts payable within one year | 44 | €102 | €182 | €149 | €61 |
| Income statement | |||||
| Gross operating margin | 9900 | €113k | €84k | €71k | €44k |
| Operating result | 9901 | €110k | €82k | €70k | €43k |
| Financial income | 75 | €0 | - | - | - |
| Financial charges | 65 | €46 | €42 | €42 | €42 |
| Result before taxes | 9903 | €110k | €82k | €70k | €43k |
| Income taxes | 67/77 | €31k | €22k | €14k | €11k |
| Net result for the period | 9904 | €79k | €59k | €56k | €32k |
| Result to be appropriated | 9905 | €79k | €59k | €56k | €32k |
Legal Structure
| NACE primary | Retail sale of pharmaceutical products(47730) |
| Legal form | Private limited company(610) |
| Incorporation | 07-10-2020 |
| Status | Active |
| Postal code | 3740 |
Establishment units
CVHD
since 20202.308.739.659
Real-estate footprint
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 73068A0361/00_000 | Flanders | 1,601 m² | 1 · 196 m² | 10.5 m · 2 fl. |
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Updates
2025
22-07
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
31-12
Financial
Highest result since 2021net €79k ▲33.4%
Operating result €110k, net result €79k, both a record.
31-12
Financial
Liquidity doublescurrent ratio 34.91
Current ratio from 14.22 to 34.91; short-term debt falls from €11k to €7k.
31-12
Financial
Equity above €200kEq €229k ▲52.7%
4 profitable years in a row build equity to €229k.
27-06
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
31-12
Financial
Equity above €100kEq €150k ▲65.2%
3 profitable years in a row build equity to €150k.
18-08
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 18 days late
2022
31-12
Financial
Liquidity doublescurrent ratio 7.25
Current ratio from 3.40 to 7.25.
01-06
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Belgian State Gazette reading coverage
We know of 2 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Credit advice
Company registry (CBE)
Activities
Retail sale of pharmaceutical products47730
Names & trade names
| Legal nameNL | CVHD |
Similar companies
PHARMACIE DE BOUSSOIT
BE 0834.774.476 · La Louvière
Pharmacie Fennia
BE 0406.552.833 · Brussel
APOTHEEK HAEGEMANS - MERTENS
BE 0433.045.909 · Herent
APOTHEEK HEYVAERTS
BE 0457.172.381 · Antwerpen
APOTHEEK VAN LANDSCHOOT
BE 0479.181.681 · Kaprijke